CLN2 neuronal ceroid lipofuscinosis is a recessively inherited lysosomal storage disease characterized by progressive motor and cognitive decline, seizures, vision loss progressing to blindness, brain and retinal atrophy, and childhood death. CLN2 disease results from mutations in the TPP1 gene that encodes the soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1). We conducted studies using a canine model of CLN2 to determine whether continuous delivery of TPP1 protein to the retina and central nervous system could delay the onset and slow progression of retinal and neuronal degeneration. 
